{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:45:44Z","timestamp":1760546744069},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1997,3,1]],"date-time":"1997-03-01T00:00:00Z","timestamp":857174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[1997,3]]},"DOI":"10.1006\/exnr.1996.6383","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T11:46:56Z","timestamp":1032176816000},"page":"24-28","source":"Crossref","is-referenced-by-count":23,"title":["Neuroprotective Therapy for Parkinson's Disease"],"prefix":"10.1006","volume":"144","author":[{"given":"William C.","family":"Koller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/exnr.1996.6383_EN966383RF1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.410320403","article-title":"Nigral damage and dopaminergic hypofunction in mesencephalon-immunized guinea pigs","volume":"32","author":"Appel","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF2","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.2402638","article-title":"Reversal of experimental parkinsonism by lesions of the subthalamic nucleus","volume":"249","author":"Bergman","year":"1990","journal-title":"Science"},{"key":"10.1006\/exnr.1996.6383_EN966383RF3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01245973","article-title":"Improvement of life expectancy due to L-deprenyl addition to madopar treatment in Parkinson's disease: A long term study","author":"Birkmayer","year":"1985","journal-title":"J. Neural Transm."},{"key":"10.1006\/exnr.1996.6383_EN966383RF4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S0317167100027499","article-title":"Late progression of post-encephalitic Parkinson's syndrome","volume":"15","author":"Calne","year":"1988","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1006\/exnr.1996.6383_EN966383RF5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1212\/WNL.41.5_Suppl_2.53","article-title":"The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease","volume":"41(Suppl. 2)","author":"Carvey","year":"1991","journal-title":"Neurology"},{"key":"10.1006\/exnr.1996.6383_EN966383RF6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0140-6736(90)91099-V","article-title":"Superoxide dismutase in Parkinson's disease","volume":"335","author":"Ceballos","year":"1990","journal-title":"Lancet"},{"key":"10.1006\/exnr.1996.6383_EN966383RF7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1006\/exnr.1996.6383_EN966383RF8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ana.410360302","article-title":"The brain on fire?","volume":"36","author":"Cohen","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0166-2236(87)90170-6","article-title":"Excitatory amino acids in the brain: Locus on NMDA receptors","volume":"10","author":"Cotman","year":"1982","journal-title":"Trends Neurosci."},{"key":"10.1006\/exnr.1996.6383_EN966383RF10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","article-title":"NMDA antagonists in the treatment of Parkinson's disease","volume":"68","author":"Greenamyre","year":"1991","journal-title":"Arch. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.410350605","article-title":"Antiparkinsonian effects of Remacemide, a glutamate antagonist in rodent and primate models of Parkinson's disease","volume":"35","author":"Greenamyer","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF12","first-page":"2768","article-title":"Nocardia serology in Parkinson's disease and clinical nocardiosis","volume":"33","author":"Hubble","year":"1995","journal-title":"J. Clin. Microbiol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(94)92347-7","article-title":"Oxidative damage in neurodegenerative disease","volume":"344","author":"Jenner","year":"1994","journal-title":"Lancet"},{"key":"10.1006\/exnr.1996.6383_EN966383RF14","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/WNL.42.12.2241","article-title":"New insights into the cause of Parkinson's disease","volume":"42","author":"Jenner","year":"1992","journal-title":"Neurology"},{"key":"10.1006\/exnr.1996.6383_EN966383RF15","first-page":"67","article-title":"Extension of life span of rats by long term (\u2212)deprenyl treatment","volume":"55","author":"Knoll","year":"1988","journal-title":"Mt. Sinai J. Med."},{"key":"10.1006\/exnr.1996.6383_EN966383RF16","first-page":"181","article-title":"L-Dopa-responsive movement disorder caused by nocardia asteroides localized in the brains of mice","volume":"59","author":"Kohbata","year":"1991","journal-title":"Infect. Immun."},{"key":"10.1006\/exnr.1996.6383_EN966383RF17","first-page":"58","article-title":"Levodopa therapy in Parkinson's disease","volume":"40(Suppl. 3)","author":"Koller","year":"1990","journal-title":"Neurology"},{"key":"10.1006\/exnr.1996.6383_EN966383RF18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.40.8.1218","article-title":"Environmental risk factors in Parkinson's disease","volume":"40","author":"Koller","year":"1990","journal-title":"Neurology"},{"key":"10.1006\/exnr.1996.6383_EN966383RF19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/1353-8020(95)00017-8","article-title":"Isolated involvement of substantia nigra or acute transient parkinsonism: MRI and PET observations","volume":"3","author":"Lin","year":"1995","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1006\/exnr.1996.6383_EN966383RF20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.410360612","article-title":"Complex I, iron, and ferritin in Parkinson's disease substantia nigra","volume":"36","author":"Mann","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410240415","article-title":"Rate of cell death in parkinsonism indicates active neuropathological process","volume":"24","author":"McGeer","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF22","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/ana.410320703","article-title":"An introduction to the free radical hypothesis in Parkinson's disease","volume":"32(Suppl.)","author":"Olanow","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF23","first-page":"13","article-title":"Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanism","volume":"42(Suppl. 6)","author":"Olanow","year":"1991","journal-title":"Neurology"},{"key":"10.1006\/exnr.1996.6383_EN966383RF24","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/ana.410320703","article-title":"Role of iron and oxidant stress in the normal and parkinsonian brain","volume":"32","author":"Olanow","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","article-title":"The effect of deprenyl and levodopa on the progression of Parkinson's disease","volume":"38","author":"Olanow","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ana.410260606","article-title":"Abnormalities of the electron transport chain in idiopathic Parkinson's disease","volume":"26","author":"Parker","year":"1989","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/exnr.1996.6383_EN966383RF28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.410390106","volume":"39","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mds.870050406","article-title":"Mitochondrial DNA analysis in Parkinson's disease","volume":"5","author":"Schapira","year":"1990","journal-title":"Mov. Disord."},{"key":"10.1006\/exnr.1996.6383_EN966383RF30","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1002\/ana.410320720","article-title":"Mitochondria function in Parkinson's disease","volume":"32(Suppl.)","author":"Schapira","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF31","first-page":"65","article-title":"Behavioral pharmacology of glutamate in the basal ganglia","volume":"38(Suppl.)","author":"Schmidt","year":"1991","journal-title":"J. Neural Transm."},{"key":"10.1006\/exnr.1996.6383_EN966383RF32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1471-4159.1990.tb01962.x","article-title":"Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on ATP levels of mouse and brain synaptosomes","volume":"54","author":"Scotcher","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.1996.6383_EN966383RF33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410360305","article-title":"Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia","volume":"36","author":"Sian","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF34","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(86)91059-7","article-title":"Motor neurone disease in Guam: Possible role of a food neurotoxin","volume":"1","author":"Spencer","year":"1986","journal-title":"Lancet"},{"key":"10.1006\/exnr.1996.6383_EN966383RF35","first-page":"17","article-title":"Do environmental toxins cause Parkinson's disease? A critical review","volume":"Suppl 3","author":"Tanner","year":"1990","journal-title":"Neurology"},{"key":"10.1006\/exnr.1996.6383_EN966383RF36","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jnr.490300410","article-title":"Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism","volume":"30","author":"Tatton","year":"1991","journal-title":"J. Neurosci. Res."},{"key":"10.1006\/exnr.1996.6383_EN966383RF37","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1046\/j.1471-4159.1994.63041572.x","article-title":"Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis","volume":"63","author":"Tatton","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1006\/exnr.1996.6383_EN966383RF38","series-title":"Neurodegeneration and Prospects for Neuroprotection in Parkinson's Disease","article-title":"Reduction of neuronal apoptosis by small molecules: Promises for new approaches to neurological therapy","author":"Tatton","year":"1996"},{"key":"10.1006\/exnr.1996.6383_EN966383RF39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1126\/science.2502843","article-title":"The effect of deprenyl (selegiline) in the natural history of Parkinson's disease","volume":"245","author":"Tetrud","year":"1989","journal-title":"Science"},{"key":"10.1006\/exnr.1996.6383_EN966383RF40","first-page":"S2","article-title":"Neurotransmitter transporter (plus): A promising new gene family","volume":"32","author":"Uhl","year":"1992","journal-title":"Trends Neurosci."},{"key":"10.1006\/exnr.1996.6383_EN966383RF41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(93)90181-G","article-title":"Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited MPP+ in vivo","volume":"243","author":"Wu","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1006\/exnr.1996.6383_EN966383RF42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(90)91236-A","article-title":"Relative sparing in Parkinson's disease of substantia nigra containing calcium-binding D 28K","volume":"526","author":"Yamada","year":"1990","journal-title":"Brain Res."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488696963839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488696963839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T05:54:35Z","timestamp":1557381275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488696963839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["S0014488696963839"],"URL":"https:\/\/doi.org\/10.1006\/exnr.1996.6383","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[1997,3]]}}}